

June 16, 2020

Listing Department

Code: **532 321**

BSE LIMITED

P J Towers, Dalal Street, Fort,
Mumbai – 400 001

Listing Department

Code: **CADILAHC**

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai – 400 051

Re.: Press Release

Dear Sir/Madam,

Please find enclosed a copy of press release dated June 16, 2020 titled “Zydus Cadila receives final approval from USFDA for Deferasirox Tablets”.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large.

Thanking you,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**

Dhaval N. Soni

DHAVAL N. SONI
COMPANY SECRETARY



Encl.: As above

Zydus Cadila receives final approval from USFDA for Deferasirox Tablets

Ahmedabad, June 16, 2020

Zydus Cadila has received final approval from the USFDA to market Deferasirox Tablets (US RLD: Jadenu™ Tablets) in the strengths of 90 mg, 180 mg and 360 mg.

Deferasirox binds to iron and removes it from the bloodstream. It is used to treat iron overload caused by blood transfusions in adults and children who are at least 2 years old. It is also used to treat chronic iron overload syndrome caused by a genetic blood disorder (non-transfusion dependent thalassemia) in adults and children who are at least 10 years old.

The drug will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.

The group now has 291 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally.
